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The adipose tissue is a good source of mesenchymal stromal cells that requires minimally invasive isolation procedures. To ensure
reproducibility, eﬃcacy, and safety for clinical uses, these procedures have to be in compliant with good manufacturing practices.
Techniques for harvesting and processing human adipose tissue have rapidly evolved in the last years, and Lipogems® represents an
innovative approach to obtain microfragmented adipose tissue in a short time, without expansion and/or enzymatic treatment. The
aim of this study was to assess the presence of mesenchymal stromal cells in the drain bag of the device by using a prototype
Lipogems processor to wash the lipoaspirate in standardized condition. We found that, besides oil and blood residues, the drain
bag contained single isolated cells easy to expand and with the typical characteristics of mesenchymal stromal cells that can be
loaded with paclitaxel to use for drug-delivery application. Our ﬁndings suggest the possibility to replace the drain bag with a
“cell culture chamber” obtaining a new integrated device that, without enzymatic treatment, can isolate and expand
mesenchymal stromal cells in one step with high good manufacturing practices compliance. This system could be used to obtain
mesenchymal stromal cells for regenerative purposes and for drug delivery.
1. Introduction
Mesenchymal stromal cells (MSCs) can be easily isolated
from several human organs and tissues and, because of
their self-renewing capacity and multipotent diﬀerentiation
properties, they are important tools for treating immune
disorder and for tissue repair. In particular, adipose-
derived MSCs (ASCs) can be harvested in high amounts
by minimally invasive procedures with good viability, dif-
ferentiating potential, and paracrine activity [1–3]. These
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cells can be also used as drug carrier (as already demon-
strated for MSCs derived from bone marrow) because,
when primed with high doses of the chemotherapeutic
drug paclitaxel (PTX), they are capable to uptake the drug
and release it in big amounts inhibiting the in vitro prolif-
eration of diﬀerent tumour cell lines [4, 5]. Their deﬁni-
tion as advanced-therapy medicinal products (ATMPs)
according to the European Medicines Agency (EMA) and
the US Food and Drug Administration requirements for
their production and use implies the application of pro-
duction processes that should be in accordance with good
manufacturing practices (GMPs). To increase safety and
reproducibility and to implement the many clinical trials
using ASCs, several methods based on reducing the
manipulation of human tissue-based products have been
suggested, in particular by using nonenzymatic treatments
[6, 7]. Among the many, an innovative closed and sterile
system (named Lipogems), designed to harvest, process,
and transfer a reﬁned and not-expanded adipose tissue
characterized by a great regenerative potential and optimal
handling, has been developed. By the aid of this technol-
ogy, and without the addition of enzymes or any other
additives, fat tissue is microfragmented in a completely
close liquid environment and washed from proinﬂamma-
tory oil and blood residues [8]. This closed and sterile
device reduces the size of the adipose tissue clusters by
means of two ﬁlters [9]. A drain bag, connected to the
second ﬁlter of the device, collects the waste ﬂuid contain-
ing red blood cells and oil residues. We used a prototype
Lipogems processor (PLG-P) to wash and process the
lipoaspirate in a standardized condition and we found
that, besides oil and blood residues, the drain bag con-
tained single isolated cells easy to expand and with the
typical characteristics of ASCs. These cells can be also
loaded with paclitaxel to provide a cell-mediated drug-
delivering tool.
2. Materials and Methods
2.1. Ethics Statements. Samples from adult donors were
collected after signed informed consent of no objection for
the use for research of surgical tissues (otherwise destined
for destruction) in accordance with the Declaration of
Helsinki. The approval for their use was obtained from
the Institutional Ethical Committee of Milan University
(n.59/15, C.E.UNIMI, 09.1115).
2.2. Prototype Lipogems Processor (PLG-P). The prototype
processor (Figure 1(a)) equipped with the Lipogems device
(Figure 1(b)) is able to guarantee digitally controlled move-
ments according to these main parameters: oscillation ampli-
tude and frequency and pitch movements and saline washing
ﬂux. 25ml of lipoaspirate was loaded in the Lipogems device
and washed according to a standardized procedure: process
ﬂow 120ml/min, oscillation frequency 2Hz, pitch frequency
0.3Hz, pitch angle 30°, and pitch axis 90° vertical (exit
bottom). In a ﬁrst preliminary experiment, the tissue was
processed for 5 minutes and cells were collected one step into
600ml of saline. In a second experiment, the collection was
fractioned and performed at 1 (120ml), 2.5 (180ml), and 5
minutes (300ml).
(a)
Lipoaspirate
Drain bag
F1 F2
Lipogems device
Pellet seeded in ask
(b)
Figure 1: DB-MSC isolation and expansion. (a) Prototype Lipogems processor (PLG-P) mounting a Lipogems device. In this closed system,
the lipoaspirate is microfragmented by using mild mechanical forces without the addition of collagenase or other enzymes/additives. (b)
Schematic representation of Lipogems device. The lipoaspirate (blue circle) is subjected to a cluster reduction by pushing the fat into the
device through the ﬁrst ﬁlter (F1). LGP-P shaking transmits a mechanical force to the stainless steel marbles contained in the device that
results into a temporary fat emulsion washed by a ﬂux of buﬀer. This allows the washing buﬀer to cross a second ﬁlter (F2) and
accumulate into the drain bag (red circle) together with oil, red blood cells, and mesenchymal stromal cells (ASCs). The pellet obtained
after centrifugation was seeded in 25 cm2 ﬂask in StemMACS medium (Miltenyi Biotec, USA) (see Materials and Methods for details).
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2.3. ASC Isolation from Drain Bag (DB-ASCs). 100ml of each
sample was centrifuged at 2500×g for 15 minutes. Pellet was
treated twice with 0.85% ammonium chloride (5 minutes at
+4°C) to partially remove red cells. Then, after three washes
with PBS 1x through centrifugation (800×g, 10 minutes),
pellet was plated on 25cm2 ﬂask (Corning, USA) with 5ml
of Stem MACS MSC Expansion Medium (Miltenyi Biotec,
Germany) and incubated at 37°C, 5% CO2. The primary
culture was expanded with 1 : 2 passages until passage num-
ber (pn) 6. At pn 2, the population doubling time (PDT)
was calculated as previously described [10].
The clonogenicity of the ASCs was evaluated as colony-
forming eﬃciency (CFE) in multiwell plates (SPL Life
Sciences, Korea) by serial dilution (from 50 cells/well to 1
cell/well) in DMEM LG media with 10% fetal bovine serum
(EuroClone, UK). After 10 days, cell colonies ﬁxed and
labeled with Crystal Violet (0.5%, Fluka, Switzerland) were
counted at the microscope (a colony formed by at least 25
cells) and the CFE as the following: CFE=average of colonies
formed× 100/number of seeded cells.
2.4. Immunohistochemical Analysis of DB-MSCs. Mesenchy-
mal cell monolayer (pn 2) was detached with trypsin-EDTA
(EuroClone, UK) and 1.7∗106 cells were placed in a 10ml
glass conical tube in 1x PBS and centrifuged at 800×g for
10 minutes. Pellet was treated for immunohistochemical
characterization as previously reported [11]. Brieﬂy, the cen-
trifuged pellet was treated 20 minutes at room temperature
with a solution of 75% methanol, 20% chloroform, and 5%
glacial acetic acid. The pellet compacted in a solid mass was
placed in an immunohistochemical cassette and immersed
in a 10% buﬀered formaldehyde solution and, after dehydra-
tion in ethanol and paraﬃn ﬁxation, the pellet was cut in sec-
tions of 4-5μm that were stored at −20°C. For phenotypic
characterization, monoclonal or polyclonal antibodies were
used using the streptavidin-biotin method with diaminoben-
zidine as chromogen. The following antibodies were used:
antismooth muscle actin (SMA), anti-CD14, anti-CD105,
and anti-neural/glial antigen 2 (NG2) (Santa Cruz Biotech-
nology, USA); anti-CD44 (Monosan, Holland); antivascular
endothelial growth factor (VEGF), anti-CD90 (Dako, Italy);
anti-CD45, anti-CD146, anti-CD31, and anti-CD34 (Leica
Biosystems, Germany).
The expression of CD73 (CD73-PE Becton Dickinson,
USA) was evaluated by ﬂow cytometry (FacsVantage SE,
Becton Dickinson, USA). Cells were washed twice in
PBS, diluted to a ﬁnal concentration of 106 cells/ml, and
incubated with the dark antibody at +4°C for 30 minutes.
The cells were then washed with PBS and analysed by
cytoﬂuorometry by acquisition of 10,000 events per sam-
ple. The results were analysed with CellQuest Pro software
(Becton Dickinson, USA).
2.5. DB-ASC Osteo-/Adipo-Diﬀerentiation Capacity. DB-
ASCs at pn 2 have been evaluated for their osteogenic and
adipogenic diﬀerentiation using a standardized procedure
[12]. As positive control, MSCs obtained from human bone
marrow (BM-MSCs) were isolated and expanded in our lab-
oratory as previously reported [5]. As negative control, MSCs
were cultured without the addition of supplements. The dif-
ferentiation was performed by plating cells in 35mm Petri
(Nunc, Germany) at a density of 50 cells/cm2 in 1ml of
STEM MACS MSC Expansion Medium (Miltenyi Biotec,
Germany). After 72 hours of incubation, the cell medium
was removed and replaced with a speciﬁc medium for
cell diﬀerentiation. To induce osteogenic diﬀerentiation
[13], cells were incubated for 14 days in DMEM medium
LG+20% fetal bovine serum in the presence of the following:
desametasone 10 nM, glycerol 2–10mM, and phosphate and
ascorbic acid 300nM (all reagents, Sigma-Aldrich, USA).
The diﬀerentiation medium was replaced every 3-4 days with
fresh medium. Cell monolayer was ﬁxed with cold methanol
for 5 minutes at −20°C, then alkaline phosphatase (ALP) was
evaluated by SIGMA FAST BCIP/NTB substrate for ALP
(Sigma-Aldrich, USA). The colorimetric reaction was
detected by optical microscope. The presence of osteo-
blasts at the mature stage was evaluated by staining with
Alizarin Red S (Sigma-Aldrich, USA). To induce adipocy-
tic diﬀerentiation, cells were cultured in DMEM LG+20%
fetal bovine serum in the presence of indomethacin
200μM (Alexis Biochemicals, USA), isobutylmethyl-
xanthine 0.5mM (AppliChem, Germany), dexamethasone
1μM, hydrocortisone 1μM insulin, and 10μg/ml (all from
Sigma-Aldrich, USA). After 10 days of incubation, the
cells were ﬁxed with 10% buﬀered formalin (Sigma-
Aldrich, USA) for 30 minutes at room temperature and
the adipocyte vacuoles present in the cell cytoplasm were
evaluated by using red lipophilic Oil Red O (Sigma-
Aldrich, USA).
2.6. Ability of DB-ASCs to Uptake and Release Paclitaxel. The
ability to incorporate and release drugs from DB-ASCs
has been assessed with a procedure already applied on
MSCs obtained from bone marrow, adipose tissue,
human gingival tissue, human ﬁbroblasts, and also blood
cells [4, 5, 10, 14–16]. The “uptake-release” method was per-
formed using paclitaxel (PTX) that is an anticancer drug with
also antiangiogenic activity. Subconﬂuent ASC cultures
(15,000 cells/cm2) were exposed to 2000 ng/ml of PTX
(Fresenius Kabi, Italy) dissolved in culture media, and
after 24 hours of incubation (37°C, 5% CO2), the cell
monolayer was washed with PBS and the cells detached,
washed by centrifugation in PBS, and subcultured in a
25 cm2 ﬂask with fresh culture media. After 48 hours,
the conditioned medium (CM) was collected and its anti-
tumour activity was evaluated in vitro. The CM from
untreated cells was used as a negative control.
2.7. Cytokines in DB-ASC Secretome. The conditioned
medium of DB-ASCs (from untreated or treated PTX cells)
was collected, and the cytokine content was evaluated using
“multiplex bead-based xMAP technology” (Bio-Plex Human
Cytokine 27-Plex Panel and Bio-Plex Human Group II Cyto-
kine 21-Plex Panel, Bio-Rad Laboratories).
2.8. In Vitro Antiproliferative Assay on CFPAC-1 of CM
from PTX-Loaded MSCs. The eﬀect of pure paclitaxel
and CM from PTX-treated ASCs (CM/PTX) against
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tumour cell proliferation has been studied in 96-multiwell
plates (Sarstedt, Germany) by using as target pancreatic
adenocarcinoma cells (CFPAC-1) [17]. Brieﬂy, 1 : 2 serial
dilutions of pure drug or ASC-CM were prepared in
100μl of culture medium/well and then to each well were
added 1000 tumour cells. After 7 days of culture at 37°C
and 5% CO2, cell growth was evaluated by MTT assay
(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium)
as previously described [5, 18]. The inhibitory concentra-
tions (IC50 and IC90) were determined according to the
Reed and Muench formula [19]. The antitumor activity
of PTXCMwas compared to that of pure PTX and expressed
as PTX equivalent concentration: PEC (ng/ml) = IC50
PTX× 100/V50 (μl/well); IC50 PTX= the concentration of
pure PTX producing 50% of inhibition; V50 is the volume
PTX-MSCs-CM able to inhibit cell proliferation by 50%.
The PEC referred to a single primed ASC was calculated as
ratio between the total amount of PEC (PEC (ng/ml)×CM
volume (ml)) and the number of cells seeded: PE release
(pg/cell) = PEC (ng tot)∗1000/number of cells seeded.
Uptake release experiments were performed in triplicate.
2.9. Statistical Analysis. Experiments were performed using
lipoaspirate from three donors and repeated in triplicate.
The reported data are expressed as mean± standard devia-
tion. If necessary, appropriate statistical tests have been
performed using GraphPad Software (GraphPad Inc., San
Diego, CA, USA). A p value≤ 0.05 was considered statisti-
cally signiﬁcant. The linearity of response and the correla-
tion were studied using regression analysis, by Excel 2007
software (Microsoft Inc.).
3. Results
3.1. DB-ASC Isolation and Expansion. The waste medium
recovered from the drain bag contained high amounts of
red cells that were removed, only partially, by the ammo-
nium chloride treatment. However, after about 7 days, the
adhered ASCs could be clearly identiﬁed, by transparency,
surrounded by a compact rug of red cells (Figures 2(a)–
2(c)). However, the adherent cells (washed every 3 days)
improve their growth and after 10 days (early adhesion)
or 15 days (late adhesion) of incubation, the cell mono-
layer (Figures 2(d) and 2(e)) was detached and primary
culture (pn 0) was quantiﬁed for the number of cells.
The MSC primary culture was subsequently expanded
by 1 : 2 serial passage until passage number 6. MSC growth
was evaluated at pn 2 by evaluating the population dou-
bling Time (PDT) and the colony-forming eﬃciency (CFE)
that resulted, respectively, 55.2± 2.3 hours (PDT) and
20.8%± 10.4% (CFE).
3.2. DB-ASC Recovery Eﬃciency. To evaluate the amount of
ASCs recovered from the lipoaspirate, the washing ﬂuid
was collected from the drain bag by two diﬀerent ways. In
a ﬁrst experiments (one-step collection), 600ml of saline
was collected after 5 minutes of washing; in a second
experiment (fractionated collection), the collection was
performed at 1 minute (120ml), 2.5 (180ml), and 5 minutes
(300ml) (Box 2F). In the one-step collection, the total
recovery resulted 40,000± 7000 ASCs/ml of lipoaspirate
with a cell viability of 83.9± 5.4% as evaluated by trypan
blue assay. By fractionated collection, the ﬁnal recovery at
5 minutes was 46,233± 4500 ASCs/ml with a viability of
98.4± 1.52. As shown, ASCs accumulate into the drain bag
according to a kinetic that collects 13.7% of cells at 1 min-
ute, 54.9% at 2.5 minutes and, at the end of the process,
the recovery (100%) is similar to what was observed in the
one-step procedure but with a higher percentage of cell
viability (Figure 2(g)).
3.3. Immunohistochemical Analysis of DB-ASCs. The immu-
nohistochemistry analysis performed on ASCs showed the
high positivity for CD44, CD90, and CD105 (>90%) and
the negativity for CD45, CD34, CD31, and CD14 hematopoi-
etic markers (Figure 3(a)). The positivity for CD73 was eval-
uated by FACS and expressed by the dot-blots (Figure 3(c)).
Signiﬁcant was also the expression of SMA (cytoplasmic and
membrane) and VEGF (cytoplasmic). Only a small percent-
age of cells are positive for CD146, whereas the presence of
reactivity for NG2 seems to be mainly expressed at the
nuclear level (Figure 3(a)).
3.4. DB-ASC Osteo-/Adipo-Diﬀerentiation Capability. The
diﬀerentiation capacity towards osteogenic and adipogenic
lineages is reported in Figure 4.
A remarkable positivity of ALP (Figure 4(d)) conﬁrms
the presence of a signiﬁcant enzymatic activity involved in
the mineralization of the bone matrix. The mature stage of
osteoblasts is conﬁrmed by the presence of calcium deposits
forming complex orange-colored bifurcations, evidenced by
the coloration with Alizarin Red S (Figure 4(b)). As shown
in Figure 4(f), DB-ASCs are also able to diﬀerentiate in adi-
pocytes as evidenced by the red intracellular inclusions. The
negative controls (DB-ASCs cultured without the addition
of supplements) do not give any evidence of diﬀerentiation
(Figures 4(a), 4(c), and 4(e)).
3.5. Ability of DB-ASCs to Uptake and Release Paclitaxel. The
conditioned media from DB-ASCs, both primed with PTX
(CM/PTX) or not (CM CTRL), were tested on the standard
laboratory tumour cell line CFPAC-1 (Figure 5). As expected,
the CM CTRL does not inhibit neoplastic growth, which
remains stable to 80–100% of proliferation (Figure 5(a)).
On the contrary, CM/PTX aﬀected CFPAC-1 cell growth
according to a dose-dependent antiproliferative eﬀect that,
even if less eﬀective, reﬂects the inhibition produced by free
PTX (from 0.39 to 50 ng/ml). The inhibitory kinetics
analysed by linear regression showed high coeﬃcients of
determination (R2) ranging from 0.71 to 0.88 (Figure 5(b)).
The biological dosage of the CM/PTX based on the standard
dose-response regression of the pure drugs enabled the esti-
mation of an equivalent paclitaxel concentration (PEC) of
3.94± 0.32 ng/ml. The amount of PTX released by a single
cell (CPR), expressed as pg/cell, was 0.14± 0.01 pg/cell (box
5C). The drug concentrations released by 106 DB-ASCs/
PTX were 140ng of PTX that correspond to values of about
10 times the IC50 value of the free drug (1.48± 0.35 ng/ml).
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3.6. Cytokines in DB-ASC Secretome. Among the 40 cyto-
kines analysed in the conditioned medium of DB-ASCs
primed or not with PTX (CM DB-ASCs; CM DB-ASCs
PTX), only those whose secretion was greater than
1000 pg/ml were considered (IL-1ra, IL-6, IL-8, IL-12
(p70), MCP-1 (MCAF), VEGF, and GROa) and reported
in Figure 6. The concentration of these cytokines in the
CM was evaluated before and after PTX treatment. As it
was shown, the PTX treatment seems to inhibit their
secretion that is expressed as percentage ranged from
22.35% (IL12 (p70)) to 70.98% (GROa) with a mean
decrease of 37.1± 15.7%.
4. Discussion
It is known that adipose tissue can be harvested by mini-
mally invasive procedures according to diﬀerent methodol-
ogies and many eﬀorts have been done to reduce the
manipulation of the biological material [6]. Lipogems
represents a very interesting technique that, without the
addition of enzymes or any other additives, microfrag-
ments the lipoaspirate in a closed liquid environment that
allows, by the protection provided by the liquid (which is
noncompressible by deﬁnition), to avoid the destruction of
the adipocytes. The ﬁnal product is a nonexpanded and
(a) (b)
(c) (d)
(e) (f)
(g)
Figure 2: Growth and recovery eﬃciency of DB-ASCs. After few days of culture, it was possible to distinguish the red blood cells from the
ASCs adherent to the ﬂask (a, b, c). In Figures (b) and (c), black arrows indicate red blood cells and white arrows ASCs. Figure (d)
represents the early adhesion (10 days at 37°C, 5% CO2), and Figure (e) the late adhesion (15 days at 37
°C, 5% CO2) of DB-ASCs. Figure
(f) reports DB-ASC recovery eﬃciency (the amount of ASCs recovered from the lipoaspirate by one-step collection and by fractionated
collection), and the histogram (g) reports the percentage recovery of ASCs by fractionated collection after 1, 2.5, and 5 minutes. Data are
expressed as mean± standard deviation (SD) of three diﬀerent measures.
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(a)
(b) (c)
Figure 3: Immunohistochemical analysis of DB-ASCs. (a) Immunohistochemical analysis for CD14, CD31, CD34, CD45, CD90, CD105,
CD44, CD146, NG2, SMA, and VEGF (all ﬁgures are 100x magniﬁcation). (b, c) FACS analysis on CD73: (b) = negative CTRL and
(c) =CD73 expression.
6 Stem Cells International
minimally manipulated adipose tissue product suitable for
clinical uses because it is in compliant with goodmanufactur-
ing practices (GMPs). As recently reviewed, Lipogems has
been used in many surgical ﬁelds such as orthopaedic, recon-
structive, and plastic surgery and oncology [20]. In order to
obtain more standardized microfragmenting conditions, a
prototype apparatus (PLG-P) has been designed that over-
coming the manual operations provides a procedure with
programmable parameters (angle and frequency of shaking
and ﬂux of washing). We mounted a Lipogems device into
the PLG-P equipped with a drain bag allowing the
collection of high volumes of the washing ﬂuid object of
our investigations (Figure 1). Our study demonstrated that
the “waste” material contained in the drain bag is surpris-
ingly a rich source of ASCs. In fact, during the long
microfragmentation process, the continuous shaking and
washing ﬂux allows to detach mechanically many ASCs
that accumulate into the drain bag. Of course, the signiﬁ-
cant amount of single isolated ASCs is diluted into the bag
due to the extensive washing volume of buﬀer used. How-
ever, these cells can be easily collected by centrifugation
and if cultured, in the presence of contaminant red cells,
are able to adhere with a signiﬁcant CFE and can be easily
expanded with a good PDT (Figure 2). These cells are pos-
itive for the expression of CD44, CD73, CD90, CD105,
SMA, VEGF, and NG2 and negative for CD14, CD31,
CD34, and CD45 and showed osteo-/adipogenic diﬀerenti-
ation capability (Figures 3 and 4). Although it is known
that the expression of these markers may depend on
culture conditions, the pattern clearly conﬁrm the mesenchy-
mal stromal cell type of DB-ASCs. Besides the positivity for
the typical MSC markers CD90, CD105, and CD73[21],
DB-ASCs are also positive for NG2 (about 50%) and SMA
(90%) that are markers commonly expressed by pericytes in
diﬀerent amount depending from the type of vessel from
which they originated (capillaries, venules, or arterioles)
[22, 23]. Lipoaspirate is very rich in microvessels, and,
therefore, a signiﬁcant amount of ASC progenitors can be
obtained with our procedure. Very few cells were positive
for CD146, probably because the expression of this marker
is reduced in the ASC population washed from lipoaspirate,
in agreement with our previous study on MSCs in Lipogems
suggesting that CD146 could stain mostly cells of endothelial
origin rather than pericytes [24].
CTRL− CTRL−
CTRL−
Oil Red S staining
Alizarin Red S staining Alkaline phosphatase staining
(a) (b) (c)
(e) (f)
(d)
Figure 4: DB-ASC osteo-/adipo-diﬀerentiation. Osteogenic diﬀerentiation evaluated in Petri dish by Alizarin Red S staining (left) and by
phosphatase alkaline staining (right). (a, c) DB-ASCs grown in control medium without supplements (negative control, CTRL−); (b, d)
positive culture (200x magniﬁcation). Adipogenic diﬀerentiation evaluated by Oil Red staining (presence of red cytoplasmic inclusions;
200x magniﬁcation). (e) Negative control (CTRL−) (200x magniﬁcation). (f) Positive culture (200x magniﬁcation).
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The possibility to estimate the cell content and, in partic-
ular, the number of ASCs/ml of lipoaspirate give importance
to this technique. Our study suggests that washing the
lipoaspirate with the PLG-P allows to collect signiﬁcant
amounts of single isolated ASCs with a recovery eﬃciency,
in terms of ASCs per ml of lipoaspirate processed, of
(a) (b)
IC50PTX (ng/ml) 1.48 ± 0.35
PEC (ng/ml) 3.94 ± 0.32
CPR (pg/cell) 0.14 ± 0.01
(c)
Figure 5: Ability of DB-ASCs to uptake and release paclitaxel. The graph reports the inhibitory activity exerted on pancreatic carcinoma
CFPAC-1 cells by (a) the conditioned medium (CM) of nontreated cells (CM CTRL) and (b) the CM of DB-ASCs loaded with PTX (CM/
PTX). The activity is compared to the inhibition exerted by pure PTX. The activity is expressed as percentage of CFPAC-1 proliferation
referred to that of untreated cells (100% proliferation). The regression and the correlation coeﬃcient (R2) of the dose-response kinetics are
also reported. The box (c) reports the IC50 value referred to PTX (ng/ml), the paclitaxel equivalent concentration (PEC), and the single
cell paclitaxel release (CPR). See details in Materials and Methods. Values are expressed as mean± standard deviation (SD) of three
independent experiments.
Cytokines
(pg/ml) CMDB‐ASCs CM DB‐ASCsPTX
IL‐1ra
IL‐6 10278.09
IL‐8 5832.56
IL‐12 (p70)
MCP‐1 (MCAF) 3433.47
VEGF 4423.49
GROa
SCGF‐b 6306.34
1077.87 736.10
7242.88
3068.68
869.601119.86
2309.90
3333.90
863.372975.18
3906.46
(a) (b)
Figure 6: Cytokines in DB-ASC secretome. (a) The table shows the amounts of cytokines (expressed in pg/ml) secreted in the conditioned
medium of DB-ASCs before (CM DB-ASCs) and after treatment with PTX (CM DB-ASCs PTX). (b) The histogram reports the decrease
of cytokines secretion by PTX-treated DB-ASCs expressed as percentage of the amount produced by the untreated DB-ASCs.
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46,233± 5500 ASCs/ml that is higher compared to what was
reported by other authors [25].
A further important observation is that the expanded
ASCs were able to uptake and then release paclitaxel
(PTX). Although the PTX treatment modiﬁed the amount
of some cytokines produced by DB-ASCs (Figure 6), this
aspect is not relevant because cells loaded with the drug are
able to release PTX in an active form as shown by the
in vitro anticancer activity of the conditioned medium
(Figure 5). The uptake-release ability of paclitaxel by DB-
MSCs is in line with our previous observations on MSCs
from diﬀerent sources (bone marrow, adipose tissue, human
gingival tissue, human ﬁbroblasts, and also blood cells) and
conﬁrms that these cells can be considered an important tool
for cell-mediated drug delivery [4, 5, 10, 14–16].
5. Conclusions
In conclusion, this system minimally manipulate the adipose
tissue thus bypassing the complex requirements of GMP
guidelines, with a dramatic reduction of the costs for cell-
based therapies on human patients. From a biotechnological
point of view, our ﬁndings suggest the possible development
of a new integrated device that operating without enzymes
allows the isolation, expansion, and drug loading of ASCs
in one single step. If equipped with selective ﬁlters and if
the drain bag will be replaced by a “cell culture chamber,”
the PLG-P+Lipogems device conﬁgures a “standardized
automated collection system” to isolate mesenchymal cells
with a “minimal manipulation” compliant with the GMP
standards [26, 27]. A system as such has the potential to
obtain MSCs not only for regenerative medicine purposes
but also for cell-mediated drug delivery.
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